Recent research publication honored by journal

Glioblastoma research by Dr. Drazen Raucher was named best paper by the journal Molecules, an MDPI publication. 

“Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy” tested whether combining two existing drugs, Temozolomide and Doxorubicin, could improve treatment of glioblastoma, an aggressive brain cancer. 

“We found that using temozolomide together with doxorubicin works better than either drug alone, even in drug-resistant cancer cells,” Raucher said. “The combination increases drug uptake into tumor cells and leads to more effective cancer cell killing. Importantly, this approach may help overcome resistance, which is a major problem in current therapies. Overall, the work suggests a promising strategy to improve outcomes for patients with this difficult-to-treat cancer.”